Every story we've covered involving 2030-goals.
Novo Nordisk shares plunged after investors reacted skeptically to the company’s outlook for 2030, as doubts mounted about its ability to meet long-term objectives. The maker of the weight-loss drug Ozempic failed to generate the positive investor response many had hoped would signal a turnaround.
No stories here yet.